Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10969
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRubinstein, Cen
dc.contributor.authorFletcher, D Ren
dc.contributor.authorShulkes, Arthuren
dc.contributor.authorHardy, Kenneth Johnen
dc.date.accessioned2015-05-16T00:32:50Z
dc.date.available2015-05-16T00:32:50Z
dc.date.issued1992-11-01en
dc.identifier.citationAustralian and New Zealand Journal of Surgery; 62(11): 892-6en
dc.identifier.govdoc20169709en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10969en
dc.description.abstractCalcitonin gene-related peptide (CGRP) is a potent vaso-active peptide. Typically, it is elevated in the plasma of patients with medullary thyroid cancer (MTC), but is undetectable in the plasma of healthy individuals. Some symptoms associated with MTC could be caused by elevated CGRP. The plasma level of CGRP was measured in patients with recurrent MTC at rest and again after intravenous pentagastrin to further elevate the CGRP. When normal subjects received pentagastrin the CGRP level still remained below the detectable threshold (< 4 pmol/L). The CGRP levels did not correlate with the patients' blood pressure but a rise in CGRP was associated with a rise in heart rate. As not all patients showed symptoms, further investigation examined the possibility of plasma elevation of somatostatin, a known inhibitor, preventing responses but no change was found. Similarly, examination of the patient plasma for CGRP fractions did not reveal any increased breakdown.en
dc.language.isoenen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCalcitonin Gene-Related Peptide.blood.drug effectsen
dc.subject.otherCarcinoma, Medullary.blood.complications.physiopathologyen
dc.subject.otherCase-Control Studiesen
dc.subject.otherHeart Rate.drug effectsen
dc.subject.otherHumansen
dc.subject.otherPentagastrin.pharmacologyen
dc.subject.otherSomatostatin.blooden
dc.subject.otherThyroid Neoplasms.blood.complications.physiopathologyen
dc.titleElevated plasma calcitonin gene-related peptide and the symptoms associated with medullary thyroid cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleAustralian and New Zealand Journal of Surgeryen
dc.identifier.affiliationDepartment of Surgery, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages892-6en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20169709en
dc.type.austinJournal Articleen
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Jan 29, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.